Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome | ||
By: Nasdaq / GlobeNewswire - 26 Jun 2019 | Back to overview list |
|
Press release – No. 16 / 2019 Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
Copenhagen, June 26, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the dosing of the first subject in a Phase 1 clinical trial to evaluate the safety and tolerability of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS). The study is a randomized, double-blind, placebo-controlled, single ascending dose trial in 64 healthy subjects, randomized to ZP7570 or placebo within eight cohorts. ZP7570, a long-acting, dual GLP-1/GLP-2 peptide therapeutic, is designed to further improve management of SBS and may represent a next level of innovation for helping SBS patients to further realize full potential for intestinal rehabilitation. GLP-2 primarily increases the absorptive capacity of the intestine, whereas GLP-1 is believed to act by reducing gastrointestinal motility, thereby allowing more time for the fluids and nutrition to be absorbed. The properties of ZP7570 may also allow for therapeutic opportunities in other gastrointestinal diseases. “We are committed to changing the lives of people with short bowel syndrome and see good progress in our Phase 3 clinical trial with glepaglutide, a potential best-in-class long-acting GLP-2 analog for treatment of SBS,” commented Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma. “Initiation of this Phase 1 clinical trial with ZP7570, a dual- GLP-1/GLP-2 acting peptide, marks yet another important milestone in our efforts to bring innovative therapeutics to patients living with SBS.” For further information, please contact: Emmanuel Dulac, President and Chief Executive Officer Lani Pollworth Morvan, Investor Relations and Communication About Short Bowel Syndrome (SBS) About Zealand Pharma A/S Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. Attachment |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |